Drug Profile

ATR 12

Alternative Names: ATR-02; ATR-12; ATR12-351; AZT-02

Latest Information Update: 26 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Azitra
Developer Azitra; The Jackson Laboratory
Class Bacteria; Gene therapies; Skin disorder therapies
Mechanism of Action Bacteria replacements; Serine peptidase inhibitor kazal-type 5 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Netherton Syndrome

Most Recent Events

24 Jul 2024 Azitra received patent grant for ATR 12 from U.S. Patent and Trademark Office (USPTO)
10 May 2024 Pharmacodynamics and adverse events data from a preclinical trial in Netherton-Syndrome released by Azitra
22 Apr 2024 Pharmacodynamics data from a preclinical trial in Netherton-Syndrome released by Azitra

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com